James Ficorilli
Eli Lilly (United States)(US)Indianapolis Zoo(US)
Publications by Year
Research Areas
Pancreatic function and diabetes, Diabetes Treatment and Management, Receptor Mechanisms and Signaling, Drug Transport and Resistance Mechanisms, Regulation of Appetite and Obesity
Most-Cited Works
- → Lipid-Based Delivery Systems for Improving the Bioavailability and Lymphatic Transport of a Poorly Water-Soluble LTB4 Inhibitor(1998)314 cited
- → Regulation of Carbohydrate Metabolism by the Farnesoid X Receptor(2004)286 cited
- → Novel Small Molecule Glucagon-Like Peptide-1 Receptor Agonist Stimulates Insulin Secretion in Rodents and From Human Islets(2010)139 cited
- → Regulation of GPR119 receptor activity with endocannabinoid-like lipids(2012)118 cited
- → Structural insights into probe-dependent positive allosterism of the GLP-1 receptor(2020)93 cited
- → Farnesoid X Receptor Agonist Reduces Serum Asymmetric Dimethylarginine Levels through Hepatic Dimethylarginine Dimethylaminohydrolase-1 Gene Regulation(2006)80 cited
- → Allosteric Modulation of Endogenous Metabolites as an Avenue for Drug Discovery(2012)78 cited
- → Positive Allosteric Modulation of the Glucagon-like Peptide-1 Receptor by Diverse Electrophiles(2016)60 cited
- → The Discovery, Preclinical, and Early Clinical Development of Potent and Selective GPR40 Agonists for the Treatment of Type 2 Diabetes Mellitus (LY2881835, LY2922083, and LY2922470)(2016)58 cited
- → β-Cell Glucagon-Like Peptide-1 Receptor Contributes to Improved Glucose Tolerance After Vertical Sleeve Gastrectomy(2016)54 cited